GlassScriptPhysician profile
Aditi Patel
NPI 1255823407
$2,379.22
in general payments reported to CMS, 2019-2025
28 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2023: $152 · 2024: $1,126 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.86 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $304.54 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $219.99 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.40 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $155.45 | 2024-2025 | Freestyle Libre |
| Alexion Pharmaceuticals, INC. | $139.04 | 2022-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $102.30 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $85.84 | 2024-2025 | Tymlos |
| Dexcom, INC. | $84.79 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $75.25 | 2024-2025 | |
| Amgen INC. | $68.12 | 2024-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $67.99 | 2025 | |
| Mannkind Corporation | $66.77 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $59.23 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $52.94 | 2024-2025 | Jatenzo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $48.93 | 2024-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $48.57 | 2024-2025 | Omnipod |
| Medtronic, INC. | $43.59 | 2024-2025 | Minimed 780g |
| Ibsa Pharma INC. | $32.88 | 2023-2025 | Tirosint, Flector, Licart |
| Rhythm Pharmaceuticals, INC. | $32.63 | 2024 | Imcivree |
| Pfizer INC. | $32.52 | 2024 | |
| Acella Pharmaceuticals, LLC | $32.26 | 2024-2025 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $30.98 | 2023-2024 | Farxiga, Lokelma |
| Sequel Med Tech, LLC | $20.41 | 2025 | Twiist |
| Antares Pharma, INC. | $19.33 | 2025 | Xyosted |
| Cequr Corporation | $17.00 | 2025 | Cequr Simplicity |
| Globus Medical, INC. | $16.93 | 2025 | Senza |
| Corcept Therapeutics | $16.81 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.